|Videos|April 9, 2021

Visus presbyopia drop gets FDA IND OK

Author(s)Rhett Schiffman, MD, MHSA, Gretchyn M. Bailey, NCLC, FAAO, Editor in Chief, Content Channel Director, Brooke Henson, Editor

A presbyopia-correcting eyedrop recently received FDA acceptance of its investigational new drug (IND) application

Rhett Schiffman, MD, MHSA, chief medical officer and head of research and development at Visus Therapeutics, talks with Gretchyn Bailey, NCLC, FAAO, editor in chief of Optometry Times® about Brimichol, the company’s presbyopia-correcting eyedrop that recently received FDA acceptance of its investigational new drug (IND) application.

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Subscribe Now!

Latest CME

In-Person Event

EnVision Summit

February 13-16, 2026

Visus presbyopia drop gets FDA IND OK

Newsletter

Related Content

What Yuvezzi brings to the optometrist's clinical toolkit with Dr Derek Cunningham

FDA approves Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for presbyopia

Pilocarpine 0.4%: Significant decrease in pupillary diameter in presbyopic patients

Deseyne EDOF daily contact lens first of its kind approved by US FDA

Refractive surgery for myopia vs presbyopia: Tailoring the approach for the individual

Latest CME

EnVision Summit

Practical Approaches to Modern Dry Eye Treatment and Management

(CME Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

(CME Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

(CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care

(CME Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

(CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

(CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

(COPE Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches

(CME Credit) Time Matters in GA: The Impact of Early Detection and Proactive Treatment Approaches

(COPE Track) The Neural Frontier: Mapping Neurostimulation Across the DED Patient Spectrum for Refractive Surgery

(COPE Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

(COPE Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

(COPE Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

(COPE Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care

(COPE Track) Patient-Centered Treatment Strategies in the Management of nAMD and DME

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

(COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

(COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience

Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience

(CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

(COPE Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

(COPE Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

(CME Track) Neurotrophic Keratitis: Multidisciplinary Approaches to Enhance Patient Outcomes

(CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

(COPE Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

(CME Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

(CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

(CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

(COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

(COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

(COPE Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Interventional Dry Eye: A Stepwise Treatment & Management Approach

Trending on Optometry Times - Clinical News & Expert Optometrist Insights

No myopia progression reported on average in 6-month trial assessing MiYOSMART iQ spectacle lenses

A preview into advances in optometry at EnVision Summit 2026

Some red light therapy devices may exceed safety levels for myopia control, study suggests

What to know about the most recent treatment and management developments in AMD

American College of Physicians policy paper advocates for scrapping the term "provider"